To pilot the feasibility of collecting patient reported outcome measures (PROMs) through the use of an existing cancer patient experiences of care survey tool.
The EQ-5D-5L set of standardised, health-related quality of life questions were added to an existing cancer patient experiences of care survey tool to measure chemotherapy patients’ self-reported outcomes. The modified survey tool underwent cognitive testing and was amended based on feedback. The EQ-5D-5L measure outcomes across five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and has been validated across a range of populations and conditions. For the PROMs section, respondents were asked to select the option that best described their health on the day they completed the survey. Those that reported having no problems were treated as a positive response.
2375 patients who received chemotherapy in 2019 participated in the survey (RR 35%). Data was collected March - June 2020. 98% of patients receiving chemotherapy were very satisfied/ satisfied with their overall care. 68% of respondents had completed their chemotherapy treatment. The PROMS results for each of the five dimensions varied. 87% of patients reported having no problems with self-care on the day they completed the survey and 63% reported no problems with mobility. Lower percentages of patients reported no problems with usual activities, anxiety/ depression and pain/ discomfort.
The results demonstrate the feasibility of using a patient experiences of care survey augmented by health-related quality of life questions. Outcome measures that received less positive responses may inform service improvement activities noting that the survey was conducted following the declaration of the pandemic hampering interpretation.